

TG THERAPEUTICS, INC.  
Form 8-K  
May 28, 2013

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **May 28, 2013**

**TG Therapeutics, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**                      **001-32639**                      **36-3898269**  
(State or Other Jurisdiction (Commission File Number) (IRS Employer Identification No.)  
of Incorporation)

**787 Seventh Ave, 48<sup>th</sup> Floor**

**New York, New York 10019**

(Address of Principal Executive Offices)

**(212) 554-4484**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ..                   Written communications pursuant to Rule 425 under the Securities Act.
- ..                   Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
- ..                   Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
- ..                   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

**Item 8.01. Other Events.**

On May 28, 2013, TG Therapeutics, Inc. (the “Company”) issued a press release announcing that its common stock had been approved for listing on the NASDAQ Capital Market (“NASDAQ”) and that it expects to commence trading on NASDAQ under the ticker symbol “TGTX” on May 30, 2013. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference.

**Item 9.01 Financial Statements And Exhibits.**

(d) Exhibits.

99.1 Press release issued by the Company on May 28, 2013.

-2-

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**TG Therapeutics, Inc.**  
(Registrant)

Date: May 28, 2013

By: /s/ Sean A. Power  
Sean A. Power  
Chief Financial Officer

INDEX TO EXHIBITS

**Exhibit  
Number Description**

99.1 Press release issued by TG Therapeutics, Inc. on May 28, 2013.

-4-